Massive 30,000-Patient trial launches to test new heart rhythm fix
NCT ID NCT07627685
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will enroll 30,000 adults in China with atrial fibrillation (a type of irregular heartbeat) that hasn't improved with medication. They will receive a new type of catheter treatment called pulse-field ablation. Researchers will track their health for up to 10 years to see how safe and effective the procedure is in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Could a new injection tame atrial fibrillation?
- Which blood thinner is safer for heart patients? a Head-to-Head test
- Can a cholesterol drug keep atrial fibrillation at bay after ablation?
- Can a One-Two punch fix a leaky heart valve and restore normal rhythm?
- Could a guided Self-Care plan tame atrial Fibrillation's return?